Dauer der doppelten Plättchenhemmung nach AMI / Stent

Similar documents
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents

Coronary Stents: Past, Present and Future

DECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.

Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo

New Generation Drug- Eluting Stent in Korea

Optimal Duration and Dose of Antiplatelet Therapy after PCI

Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients

Disclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None

Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland

Is there enough evidence for DAPT after endovascular intervention for PAOD?

P2Y 12 blockade. To load or not to load before the cath lab?

DAPT in CAD, Acute & Chronic CAD, antiplatelet therapy non-responders

Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy

Oral Antiplatelet Therapy in PCI/ACS. Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine

Moins de 6 mois d antiagrégants après DES?

Reduction in Stent Thrombosis better tablets or better stents?

Dual Antiplatelet duration in ACS: too long or too short?

Antiplatelet Therapy After PCI: How Much and How Long?

BIOFLOW-III an all comers registry with a Sirolimus Eluting Stent: Presentation of 1-Year TLF Data in patients with complex lesions

Platelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary

Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά

Quale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor

How Long Patietns Will Be on Dual Antiplatelet Therapy?

Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)

ISAR-LEFT MAIN 2 Randomized Trial. Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions

David E. Kandzari, MD Director, Interventional Cardiology Research Scripps Clinic La Jolla, California

Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management

SCAAR: Lower late and very late stent thrombosis rates with new generation drug eluting stents compared to bare metal stents

Optimal lenght of DAPT in different clinical scenarios

Biosensors Lunch Symposium

SKG Congress, 2015 EVOLVE II. Stephan Windecker

TRIAL UPDATE 1. ISAR TRIPLE SECURITY Trial. Dr Deven Patel Royal Free Hospital

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions

Polymer-Free Stent CX - ISAR

Clinical and Economic Value of Rivaroxaban in Coronary Artery Disease

Safety of Drug-Eluting Stents in Acute Coronary Syndromes

ANTIPLATELET REGIMENS:

A new era in the treatment of peripheral artery disease (PAD)?

New insights in stent thrombosis: Platelet function monitoring. Franz-Josef Neumann Herz-Zentrum Bad Krozingen

PCI for Left Main Coronary Artery Stenosis. Jean Fajadet Clinique Pasteur, Toulouse, France

HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?

Which drug do you prefer for stable CAD? - P2Y12 inhibitor

Coronary Stent Choice in Patients With Diabetes Mellitus

A patient with an acute coronary syndrome one year ago. Options for antiplatelet treatment

Clopidogrel vs New Antiplatelet Therapy (Prasugrel) Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany

Razionale ed evidenze scientifiche di Doppia Antiaggregazione Piastrinica a lungo termine nel Paziente con Sindrome Coronarica Acuta

Stent Thrombosis Importance of Pharmacotherapy

Taking DES technology from concept to long term clinical evidence. Aurore Bouvier Global Product Manager Biosensors Europe

PROMUS Element Experience In AMC

Left Main PCI vs. CABG: Real World

Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center

Nobori Clinical Studies Up-dates. Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy

Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015

PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia study

Dual Antiplatelet Therapy Made Practical

Bern-Rotterdam Cohort Study

Drug eluting stents From revolution to evolution. Current limitations

C.R.E.D.O. Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind Placebo Controlled Trial

INDEX 1 INTRODUCTION DEVICE DESCRIPTION CLINICAL PROGRAM FIRST-IN-MAN CLINICAL INVESTIGATION OF THE AMAZONIA SIR STENT...

Bioresorbable polymer drug-eluting stents in PCI

Conflict of interest :None. Meta-analysis. Zhangwei Chen, MD

Role of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University

Case Challenges in ACS The Very Elderly in the Cath Lab

Antithrombotic Therapy for Long-Term Secondary Prevention Considerations for Long-Term DAPT

From STEMIs to Stents: Updates in PCI practice

DAPT Management 2015 Michael Rinaldi, MD

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

Προβληματισμοι στην χρηση αντιαιμοπεταλιακων στα οξέα ισχαιμικά σύνδρομα

TLR des Stents Actifs

Supplementary Online Content

Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program

Twenty years of coronary angioplasty

MINERVA MEDICA COPYRIGHT. Aspirin is accepted as standard antiplatelet. Dual antiplatelet therapy for primary and secondary prevention

Assessing Myocardium at Risk: Applying SYNTAX

Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network

Clopidogrel has been evaluated in clinical trials that included cardiovascular patients

EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017

Stent Thrombosis: Patient, Procedural, and Stent Factors. Eugene Mc Fadden Cork, Ireland

Innovation in Cardiovascular Interventions. New DES, Scaffolds and other Devices Have Angioplasty Results Improved

DES in Diabetic Patients

Belinda Green, Cardiologist, SDHB, 2016

Mid-term results from real-world REPARA registry. Felipe Hernandez, on behalf of the REPARA investigators

Antiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology

Anti-platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib!

PCI with Polymer-free Stent

Do the New DAPT Guidelines Result in Any Real Changes in Practice?

Upstream P2Y 12 RB. Stefano Savonitto Divisione di Cardiologia Arcispedale S. Maria Nuova Reggio Emilia

Learning Objectives. Epidemiology of Acute Coronary Syndrome

A Large Prospective Randomized Trial of DES vs BMS in Patients with STEMI

Update on Antiplatelet Therapy

Additional Contributor: Glenn Levine (USA).

Medical Therapy for Peripheral Artery Disease

DUREE de la BITHERAPIE dans les ETUDES LEADERS. J BERLAND Clinique Saint Hilaire ROUEN

Updated and Guideline Based Treatment of Patients with STEMI

UPDATES FROM THE 2018 ANTIPLATELET GUIDELINES

Drug Eluting Stents overhyped, overused and overpriced?

The Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI

PCI in Patients with AF Optimizing Oral Anticoagulation Regimen

ΑΓΓΕΙΟΠΛΑΣΤΙΚΗ ΣΤΟ ΔΙΑΒΗΤΙΚΟ ΑΣΘΕΝΗ

Transcription:

Dauer der doppelten Plättchenhemmung nach AMI / Stent Kardio-Lunch 04.06.2014 Christoph Kaiser Universitätsspital Basel Christoph.kaiser@usb.ch

DAPT after Stenting 257 patients with PCI & stent: ASS & Ticlopidin vs. Marcoumar & Heparin & ASS Primary endpoint: cardiac death, MI, CABG, TVR < 30 days Schömig A, et al. N Engl J Med 1996;1084-89

DAPT after Stenting 1 653 mostly stable patients with PCI & stent Primary endpoint: death, TLR, stent thrombosis, MI < 30 days Leon M; N Engl J Med 1998;1665-71

DAPT after Stenting 1 653 mostly stable patients with PCI & stent Primary endpoint: death, TLR, stent thrombosis, MI < 30 days Leon M; N Engl J Med 1998;1665-71

DAPT and ACS CURE-Trial: 12 562 patients with NSTEMI-ACS; ASS & Clopidogrel vs ASS & Placebo over 12 months 11.4% 9.3% 20% RRR P < 0.001 CURE-Investigators, N Engl J Med. 2001;345:494-502

Long-Term DAPT after Stenting CREDO-Trial: 2 216 patients with elective stenting: ASS and Clopidogrel vs ASS and Placebo over 12 months Steinhubl SR et al. JAMA 2002;288:2411-21

DAPT in high-risk patients? CHARISMA: 15 603 with cv-disease or multiple risk factors: Clopidogrel & ASS versus ASS alone for 28 months Primary endpoint: composite of MI, stroke or cardiovascular death Bhatt DL, N Engl J Med 2006;354:1706-17

DAPT in high-risk patients? CHARISMA: 15 603 with cv-disease or multiple risk factors: Clopidogrel & ASS versus ASS alone for 28 months Primary endpoint: composite of MI, stroke or cardiovascular death Bhatt DL, N Engl J Med 2006;354:1706-17

DAPT in high-risk patients? CHARISMA: 15 603 with cv-disease or multiple risk factors: Clopidogrel & ASS versus ASS alone for 28 months Primary endpoint: composite of MI, stroke or cardiovascular death P=0.22% Bhatt DL, N Engl J Med 2006;354:1706-17

DAPT in high-risk patients? CHARISMA: 15 603 with cv-disease or multiple risk factors: Clopidogrel & ASS versus ASS alone for 28 months Primary endpoint: composite of MI, stroke or cardiovascular death Bhatt DL, N Engl J Med 2006;354:1706-17

2006-2014 DAPT for 12 Months After ACS and DES

2005: ACC & ESC DES - Firestorm Bern-Rotterdam registry: n=8 146, PES and SES 0,6% per year Daemen J, et al. Lancet 2007;369:667-78

Time Course of bleeding under DAPT CHARISMA: 15 603 with cv-disease or multiple risk factors: Clopidogrel & ASS versus ASS alone for 28 months Bleeding 0-12 months Bleeding 12-30 months Berger P et al. Circulation 2010;121:2575-83

The threat of late/very late stent thrombosis Mauri L, et al. Am Heart J 2010;160:1035-41

From 2005: Introduction of 2nd generation DES 1st generation DES: Taxus Cypher no more available!!!! 2nd generation DES: Endeavor Family Xience Family Orsiro Nobori Biomatrix Family.

What s different in 2nd generation DES?? New platforms and alloys (Cobalt-chromium, thinner struts) New drugs (Everolimus, Biolimus, Zotarolimus, no Paclitaxel) Less drugs, different release-kinetics New polymers, biodegradable polymers Progress in implantation techniques

The effect of 2nd generation DES and Time

Stent thrombosis with 2nd generation DES Single center: n=3 844 Metaanalysis, n= 12 866 Dores H, et al. J Invasive Cardio. 2013;25:330-6 Philip, F, et al. Circ Cardiovasc Interv 2014;7:49-61

DAPT-duration after elective stenting PODIGRY: 6 versus 12 month DAPT after coronary stenting (n= 1 970) Primary Endpoint: composite death, MI and stroke Pirmary EP Death ST MI Stroke Valgimigli M, et al. Circulation 2012;125:2015-26

DAPT-duration after elective stenting 2014 ESC-Guidelines on myocardial revascularization

AHA 2014 - The opposite: Extension of DAPT-duration after stenting

Extension of DAPT-duration after stenting Mauri L, et al. N Engl J Med 2014;371:2155-66

Extension of DAPT-duration after stenting Mauri L, et al. N Engl J Med 2014;371:2155-66

Extension of DAPT-duration after stenting 75% elective Mauri L, et al. N Engl J Med 2014;371:2155-66

Extension of DAPT-duration after stenting Mauri L, et al. N Engl J Med 2014;371:2155-66

Extension of DAPT-duration after stenting Mauri L, et al. N Engl J Med 2014;371:2155-66

Extension of DAPT-duration after stenting Mauri L, et al. N Engl J Med 2014;371:2155-66

Extension of DAPT-duration after stenting

Extension of DAPT-duration after stenting My personal conclusions: Patients after coronary stenting remain at high risk for ischemic events DAPT: Effect of DAPT >1 year is due to a) first generation DES used and b) successful secondary prevention in high-risk subsets The benefit of DAPT > 1year is tempered by an increase in bleeding events (relative increase 61%)

ESC 2015 Extension of DAPT-duration after MI due to introduction of 2nd generation Thioenopyridines

2nd generation Thioenopyridines n= 13 608 n= 18 624 Wiviott S et al. N Engl J Med 2007;357:2001-15 Wallentin L et al. N Engl J Med 2009:361:1-13

Extension of DAPT-duration after MI REACH-Registry: n=64 977 > 45 years old: 4 year outcomes Bhatt DL, et al. JAMA 2010;304:1350-7

Extension of DAPT-duration after MI CHARISMA: Clopidogrel & ASS versus ASS alone for 28 months post-hoc exploratory subgroup with prior MI without prior MI Bhatt DL at al. J Am Coll Cardiol. 2007;49:1982-88

Extension of DAPT-duration after MI Bonaca MP, et al. N Engl J Med 2015;372:1791-800

Extension of DAPT-duration after MI Bonaca MP, et al. N Engl J Med 2015;372:1791-800

Extension of DAPT-duration after MI Bonaca MP, et al. N Engl J Med 2015;372:1791-800

Extension of DAPT-duration after MI Bonaca MP, et al. N Engl J Med 2015;372:1791-800

Extension of DAPT-duration after MI Bonaca MP, et al. N Engl J Med 2015;372:1791-800

Extension of DAPT-duration after MI Bonaca MP, et al. N Engl J Med 2015;372:1791-800 Prof. D. Trenk, Herzzentrum Bad Krozingen

Extension of DAPT-duration after MI Bonaca MP, et al. N Engl J Med 2015;372:1791-800

Extension of DAPT-duration after MI Bonaca MP, et al. N Engl J Med 2015;372:1791-800 Prof. D. Trenk, Herzzentrum Bad Krozingen

Extension of DAPT-duration after MI My personal conclusions: Patients after myocardial infarction remain at high risk for ischemic events Long-term DAPT with Ticagrelor & ASS reduce the risk of CV-death, MI or stroke in high-rsik patients after myocardial infarction Long-term DAPT with Ticagrelor & ASS increases the risk of major bleeding The two doses of Ticagrelor had similar overall efficacy, but bleeding and other side effects tended to be less frequent with 60mg bid po

Near future I: Guideline Update

Near future II: Rather Mono than Bi

Besten Dank für Ihre Aufmerksamkeit!